Promising data for onvansertib in combination with standard-of-care
Findings from Cardiff Oncology’s Phase Ib portion of the Phase Ib/II study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) have been published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The publication underscores the safety… Read More
